BridgeBio Pharma Acquires 36.35% of Eidos Therapeutics Shares

BridgeBio Pharma (Nasdaq: BBIO), a genetic-disease biotechnology company, is acquiring the remaining 36.35% of shares outstanding in Eidos Therapeutics (Nasdaq: EIDX), a specialized clinical-stage biotechnology company, for $1.03 billion.

Morrow Sodali acted as the proxy solicitor for the bidder in this transaction.

Find more information here.